Tumor Necrosis Factor Inhibitors and Risk of Serious Infections in Pregnant Women With Chronic Inflammatory Diseases.

ABSTRACT:

Objective

Tumor necrosis factor inhibitors (TNFi) are used by over 20% of pregnant women with chronic inflammatory diseases, which could further impede immune function and increase the risk of infections that require hospitalization. We assessed the risk of serious infections during pregnancy and postpartum between women exposed and unexposed to TNFi with chronic inflammatory diseases.

Methods

Using MarketScan, we identified pregnant women with chronic inflammatory diseases and modeled TNFi exposure during pregnancy and postpartum as a time-varying variable. Cox proportional hazards models estimated adjusted hazard ratios (HRs) for TNFi and the risk of hospitalized infection.

Results

We followed a total of 62,813 women who had 70,529 pregnancies and 69,412 births. Amo

SUBMITTER: Flatman LK 

PROVIDER: S-EPMC12582638 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature